Quarterly ResultMay 7, 2026, 05:17 PM
Gilead Q1 Net Income +54% to $2.02B; Revenue $6.96B
AI Summary
Gilead Sciences reported a strong first quarter for 2026, with net income increasing by 54% to $2.02 billion and total revenues rising 4.4% to $6.96 billion. Basic earnings per share also saw a significant jump of 53.8% to $1.63. The company also announced several strategic acquisitions post-period, including Arcellx for approximately $7.1 billion, Tubulis for up to $5.1 billion, and Ouro Medicines for up to $2.2 billion, alongside a new collaboration with Galapagos.
Key Highlights
- Net income surged 53.7% to $2.02 billion for Q1 2026, up from $1.31 billion in Q1 2025.
- Total revenues increased 4.4% to $6.96 billion in Q1 2026, compared to $6.67 billion in Q1 2025.
- Basic earnings per share rose 53.8% to $1.63 in Q1 2026, from $1.06 in Q1 2025.
- Net cash provided by operating activities increased 44.8% to $2.54 billion in Q1 2026.
- Acquired Arcellx for ~$7.1 billion in April 2026, enhancing CAR T-cell therapy pipeline.
- Agreed to acquire Tubulis for up to $5.1 billion in April 2026, adding ADC therapies.
- Agreed to acquire Ouro Medicines for up to $2.2 billion in March 2026, focusing on TCE therapies.
- Declared dividends of $0.82 per share ($1.04 billion total) in Q1 2026.